Telix Pharmaceuticals: Revenue Up 56%, Profit Jumps 860%, and More Growth Expected in FY 2025

2 min read | February 21, 2025 11:13 AM AEDT | By Team Kalkine Media

Telix Pharmaceuticals: Revenue Up 56%, Profit Jumps 860%, and More Growth Expected in FY 2025 — Image source: Shutterstock

Impressive Financial Performance in FY 2024

For the 12 months ended 31 December 2024, Telix recorded:

Revenue growth of 56% to $783.2 million, exceeding its guidance range of $745 million to $776 million.
Profit after tax skyrocketed 860% to $49.9 million.
Operating profit surged 423% to $82.1 million.
Cost of sales rose 45% to $273.6 million, while R&D spending increased 51% to $194.6 million.

The strong performance was driven primarily by sales of Illuccix, Telix’s leading imaging agent for prostate cancer detection.

Optimistic Growth Outlook for FY 2025

Management expects strong sales momentum to continue, guiding for FY 2025 revenue between $1.18 billion and $1.23 billion, representing a 51% to 57% year-on-year increase.

Notably, this revenue forecast excludes potential earnings from upcoming products awaiting marketing approval, such as Gozellix, Pixclara, and Zircaix.

Additionally, R&D expenditure is expected to rise between 20% and 25%, as the company continues to invest in its pipeline of innovative treatments.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.